Venous Thromboembolism in Advanced Disease

Dr Simon Noble is a Clinical Senior Lecturer and Honorary Consultant in Palliative Medicine, Cardiff University and the Royal Gwent Hospital in Wales. His research interests include the management of venous thromboembolism in advanced cancer and the anticancer effects of low molecular weight heparins. He has chaired the APM Task group for the management of VTE in palliative care and is a Trustee of Lifeblood: a UK-based thrombosis charity.Dr Miriam Johnson is a Senior Lecturer in Palliative Medicine at Hull-York Medical School and Honorary Consultant to St. Catherine's Hospice, North Yorkshire, UK. Her research interests include the management of venous thromboembolism in advanced cancer, which formed the basis of her MD thesis. Her other research interests include the palliative care of patients with end stage heart failure, and the symptom management of breathlessness. She was part of the APM Task group for the management ofVTE in palliative care.Dr Lee is the co-principal investigator of the CLOT study (Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer), a landmark study that established low-molecular-weight heparin as the treatment of choice for preventing recurrent venous thromboembolism in cancer patients. Her current research activities include studies in catheter-related thromobosis, diagnosis of deep veinthrombosis and pulmonary embolism in pregnant women, and thromboprophylaxis in patients undergoing major orthpaedic surgery. She is also involved in translational research exploring the role of coagulation in cancer biology. She is a co-chair of the subcommittee on Hemostasis and Malignancy of theInternational Society of Thrombosis and Haemostasis and has chaired various educational sessions at annual meetings at the American Society of Hematology and the American Society of Clinical Oncology.